Cortexin

Ischemia and I/R groups showed significantly increased TOS and decreased TAS versus control.; OPG, RANK, RANKL, and TRPC1 expression was significantly elevated in ischemia and I/R groups.; Cortexin significantly reduced TOS and increased TAS, with 2 mg/kg producing TAS above control levels.; Cortexin significantly decreased expression of all assessed markers, with no significant difference between ischemia and I/R groups.

MK-801 model showed higher correlation with schizophrenia patient gene expression (r=0.40) than MAM model (r=0.15).; 11 of 28 co-expression modules were significantly associated with schizophrenia-related behavioral endophenotypes.; Brown module linked to hyperlocomotion was enriched in Wnt signaling; darkgrey module linked to social withdrawal was enriched in PI3K/Akt signaling.; Inhibiting these pathways specifically corrected corresponding behavioral anomalies in the MK-801 model.

Group I (Cortexin + Recognan + high-intensity magnetic stimulation) had a 27% reduction in lower limb spasticity on day 14, versus 25% in Group II and 15% in Group III.; USDG showed increased maximum and linear blood flow velocity in right and left vertebral arteries in 52% of Group I patients, compared to 41% in Group II and 20% in Group III.; Mean NIH Stroke Scale score at discharge for Group I was 9.3 ± 0.2 points and Rankin scale score was 2.1 ± 0.2 points.; A multimodal approach combining neuroprotective medications with high-intensity magnetic therapy demonstrated considerable therapeutic efficacy in ischemic stroke rehabilitation.

Children with SCT had significantly more pronounced asthenic symptoms and higher prevalence of comorbid learning disorders than children with ADHD-C and healthy peers.; Quantitative EEG showed a reduced theta-to-alpha wave power ratio in the anterior cerebral cortex of the SCT group compared with the ADHD cohort.; Findings suggest SCT involves less deficit in inhibition processes but a decline in overall functional activity maintenance.; After Cortexin treatment, 82% of cases improved in inattention, working memory impairment, asthenic symptoms, and reading skills, with EEG showing reduced alpha-band power in frontal and central leads.

Both ethanol-induced toxic CNS damage and neonatal ischemia-hypoxia trauma produced pronounced neurological deficits in rat offspring, including decreased motor activity and sensorimotor and coordination disorders.; Cortexin administered intramuscularly or rectally reduced neurological deficit severity (mNSS), improved motor activity (Open Field), enhanced Adhesive Removal and Rotarod performance, and decreased structural brain changes.; Histological examination showed reduced neuronal damage in multiple cortical regions with a significant increase in normal, unchanged neurons compared to placebo groups.; Radiolabeled Na125I cortexin distribution in brain tissue was similar across administration routes and primarily dependent on blood concentration, which was influenced by the route of administration, indicating it reaches systemic circulation and crosses the blood-brain barrier.

Anxiety and depression are prevalent in a majority of rosacea patients.; Age and gender modulate the psychiatric burden associated with rosacea.; Inflammatory mediators, lipid metabolism, and neurotropic factors are implicated in the rosacea-psychiatric link.; Dermatologists should adopt interdisciplinary treatment plans to address psychological sequelae.

mRS 0-2 at day 90 was achieved by 93.64% of the intravenous group and 86.50% of the intramuscular group; NIHSS total score decreased by 3.93 (IV) and 3.72 (IM) by the end of follow-up; MMSE mean score dynamics were 4.11 (IV) versus 3.88 (IM), p=0.249; Adverse events were comparable: 74 AEs in 60 patients (IV) versus 51 AEs in 41 patients (IM), p>0.05

MoCA scores improved significantly from 25.1 to 28.4 after two courses of Cortexin.; Cognitive improvements were maintained at delayed testing (28.0 points).; Quality of life (SF-36) showed significant improvement after the fourth visit and persisted positively.; Cortexin was effective, safe, and well tolerated in young post-stroke patients.

What is Cortexin?

**Mechanism of Action** Cortexin is a low-molecular-weight polypeptide complex extracted from bovine cerebral cortex. It is proposed to exert neuroprotective and nootropic effects through multiple mechanisms, including modulation of GABAergic and glutamatergic neurotransmission, reduction of oxidative stress, and enhan

How does Cortexin work?

Bovine cortex-derived polypeptide complex used clinically in Eastern Europe for encephalopathy and cognitive disorders.

What is the research status of Cortexin?

Cortexin is currently classified as clinical trials, with 204 research references on record. This is for research purposes only and is not medical advice.